An optimistic take on remdesivir 

A new analyst report concludes that Gilead’s remdesivir could be approved for Covid-19 quite soon.

Piper Sandler noted that there are already some encouraging data on favipiravir, a drug from Japan’s Fujifilm Toyama Chemical that has a similar mechanisms. Remdesivir "appears to be much more potent, safer … and less likely to develop resistance” than favipiravir, the note said.

One caveat: The favipiravir data were based in results in only 200 patients. Still, Gilead stock rose 3% on the news.